Latest Safety News

D3 Energy has overcome a brief weather-induced pause at its Nooitgedacht helium project in South Africa, with drilling operations set to restart and production testing planned shortly.

New Hope Group exceeded its FY26 coal production and sales guidance, driven by strong performances at Bengalla and New Acland mines, alongside a notable price uplift amid global supply tightness.

Dimerix has secured full sponsorship of the US Investigational New Drug application for its Phase 2-ready kidney drug DMX-652, setting the stage for a clinical trial targeting acute kidney injury in late 2026.

OncoSil Medical has won FDA Humanitarian Device Exemption approval for its OncoSil™ device to treat distal cholangiocarcinoma, opening a US market estimated at A$80 million annually.

Lendlease posted a statutory loss of $749 million in FY26, weighed down by impairments in its Capital Release Unit, while its core Investments, Development, and Construction segments delivered solid operating profits and secured significant new projects.

GWA Group posted modest revenue and earnings growth in FY26, driven by volume gains across Australia, New Zealand, and the UK, while raising dividends and advancing strategic priorities despite challenging market conditions.

Novo Resources has progressed its Belltopper Gold Project with a planned diamond drilling campaign and completed maiden Pilbara drilling programs, while reporting a $3.9 million net loss for H1 2026 and bolstering liquidity through capital raises.

ResMed Inc. posted a 10% rise in fiscal 2026 revenue to $5.65 billion, bolstered by the acquisition of Noctrix Health and an agreement to sell its MatrixCare business. The company continues to invest in AI-powered digital health solutions amid ongoing patent litigation and a shifting regulatory landscape.

Mayfield Childcare's Mayfield 360 division has achieved registration as an NDIS provider, enabling it to expand early intervention support services and transition from pilot to billable operations.

Orora’s FY26 results reveal a $616.6 million statutory loss driven by a $742.8 million Glass impairment, offset by robust growth in its Cans business and disciplined capital management.

NeuroScientific Biopharmaceuticals (ASX:NSB) has locked in a key FDA Pre-IND meeting for late August, advancing its Phase 2 trial plans for StemSmart™ targeting refractory Crohn’s disease in the US and Australia.

Transurban's FY26 results reveal a sharp profit rise, robust traffic growth, and major infrastructure completions, alongside a landmark NSW toll reform deal.